Understanding of the risks associated with FMEA is crucial in lot release testing.
Report: Biologics contribute to rebirth of biopharma innovation.
Time and sensitivity are essential for analytical technologies in all phases of biopharma development.
Heightened global uncertainty could slow bio/pharma development activity.
Industry experts discuss what the outsourcing market holds for 2016.
AMRI adds analytical capabilities to its outsourcing services offerings with the acquisition of Whitehouse Labs.
CMO industry consolidation may be frustrated by a dearth of attractive assets.
FDA and industry see progress and challenges in bringing cutting-edge medicines to patients.
CDER’s Office of Pharmaceutical Quality plans on promoting modernization as a way to ensure drug quality.
Can the feds negotiate Medicare Part D prices?